Combination inhibition of the renin-angiotensin system: is more better? (Q37883908)

24 August 2017

1 reference

title

Combination inhibition of the renin-angiotensin system: is more better? (English)

1 reference

24 August 2017

Michelle W Krause

1

1 reference

24 August 2017

Vivian A Fonseca

series ordinal

2

1 reference

24 August 2017

Sudhir V Shah

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

80

1 reference

24 August 2017

3

1 reference

24 August 2017

245-255

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2011.142

24 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

STUDIES ON EXPERIMENTAL HYPERTENSION : I. THE PRODUCTION OF PERSISTENT ELEVATION OF SYSTOLIC BLOOD PRESSURE BY MEANS OF RENAL ISCHEMIA.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

The renin-angiotensin system in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

An enzyme in microsomal fraction of kidney that inactivates bradykinin.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

The role of the renin-angiotensin system in the development of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Rationale for double renin-angiotensin-aldosterone system blockade

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Essential hypertension: renin and aldosterone, heart attack and stroke.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Pathophysiology of Progressive Nephropathies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Proinflammatory actions of angiotensins.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Dual renin-angiotensin system blockade and kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

ONTARGET should not be over interpreted

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Proteinuria: Is the ONTARGET renal substudy actually off target?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Acute kidney injury increases risk of ESRD among elderly

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Role of remission clinics in the longitudinal treatment of CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Surrogate Endpoints And FDA’s Accelerated Approval Process

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

https://api.crossref.org/works/10.1038%2FKI.2011.142

1 reference

7 January 2021

Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Controversy about COOPERATE ABPM trial data

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

The COOPERATE trial: a letter of concern

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

The HALT polycystic kidney disease trials: design and implementation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Supramaximal dose of candesartan in proteinuric renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Renin inhibition: what are the therapeutic opportunities?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Environmental lead exposure and progression of chronic renal diseases in patients without diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Urinary fatty acid binding protein in renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.142

7 January 2021

Identifiers

DOI

10.1038/KI.2011.142

1 reference

Dimensions Publication ID

24 August 2017

0 references

1 reference